As discussed above, pharmacological targeting of specific metabolic transporters and enzymes downstream of the PI3K/Akt signaling might offer interesting alternative anti-cancer strategies to PI3K and Akt inhibitors (Table 1). Here, AKT1 is linked to cancer.